The important role of nNOS-NO signaling in IFN-γ-stimulated melanoma progression and PD-L1-mediated immunosuppression provides a unique strategy for adjuvant treatment of melanoma by targeting the IFN-γ-nNOS-NO-PD-L1 signaling axis (Fig. 6). This evidence concerns the gene IFNG and melanoma.